Patents by Inventor Young Eun Woo
Young Eun Woo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872283Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: GrantFiled: July 9, 2019Date of Patent: January 16, 2024Assignee: Hanmi Science Co., LtdInventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
-
Publication number: 20190321485Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: ApplicationFiled: July 9, 2019Publication date: October 24, 2019Inventors: SUNG YOUB JUNG, DAE JIN KIM, SUNG HEE PARK, YOUNG EUN WOO, IN YOUNG CHOI, SE CHANG KWON
-
Patent number: 10363320Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: GrantFiled: June 28, 2017Date of Patent: July 30, 2019Assignee: Hanmi Science Co., Ltd.Inventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
-
Patent number: 10251957Abstract: The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.Type: GrantFiled: June 1, 2012Date of Patent: April 9, 2019Assignee: HANMI SCIENCE CO., LTD.Inventors: Young Eun Woo, Myung Hyun Jang, Young Jin Park, Young Kyung Park, Chang Ki Lim, Se Chang Kwon
-
Publication number: 20190083579Abstract: The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.Type: ApplicationFiled: November 30, 2018Publication date: March 21, 2019Applicant: HANMI SCIENCE CO., LTD.Inventors: Young Eun WOO, Myung Hyun JANG, Young Jin PARK, Young Kyung PARK, Chang Ki LIM, Se Chang KWON
-
Publication number: 20170340753Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: ApplicationFiled: June 28, 2017Publication date: November 30, 2017Inventors: SUNG YOUB JUNG, DAE JIN KIM, SUNG HEE PARK, YOUNG EUN WOO, IN YOUNG CHOI, SE CHANG KWON
-
Patent number: 9789202Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.Type: GrantFiled: September 5, 2012Date of Patent: October 17, 2017Assignees: HANMI SCIENCE CO., LTD., BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
-
Patent number: 9731031Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: GrantFiled: June 15, 2012Date of Patent: August 15, 2017Assignee: Hanmi Science Co., Ltd.Inventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
-
Patent number: 9072794Abstract: Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.Type: GrantFiled: July 21, 2011Date of Patent: July 7, 2015Assignee: HANMI SCIENCE CO., LTDInventors: Young Eun Woo, Jong Soo Lee, Ling Ai Shen, Dae Jin Kim, Sung Youb Jung, In Young Choi, Se Chang Kwon
-
Publication number: 20140219961Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.Type: ApplicationFiled: September 5, 2012Publication date: August 7, 2014Applicants: BEIJING HANMI PHARMACEUTICAL CO., LTD., HANMI SCIENCE CO., LTD.Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
-
Publication number: 20140212440Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.Type: ApplicationFiled: June 15, 2012Publication date: July 31, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
-
Publication number: 20140120120Abstract: The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.Type: ApplicationFiled: June 1, 2012Publication date: May 1, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Young Eun Woo, Myung Hyun Jang, Young Jin Park, Young Kyung Park, Chang Ki Lim, Se Chang Kwon
-
Publication number: 20130122023Abstract: Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Young Eun Woo, Jong Soo Lee, Ling Ai Shen, Dae Jin Kim, Sung Youb Jung, In Young Choi, Se Chang Kwon